Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprachoroidal triamcinolone acetonide in retinal diseases
NCT05496530Unknown
- Sponsor
- Benha University
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of triamcinolone acetonide in diabetic macular edema (DME), Vogt-Koyanagi-Harada disease (VKH) and retinal vein occlusion (RVO) (3 arms), sponsored by Benha University. Primary endpoint: Visual acuity at 1 year. Status: unknown.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)Vogt-Koyanagi-Harada disease (VKH)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT05496530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496530.